Corvus Pharmaceuticals In... (CRVS)
| Bid | 3.2 |
| Market Cap | 233.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68.44M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -3.36 |
| Forward PE | -11 |
| Analyst | Buy |
| Ask | 3.49 |
| Volume | 485,071 |
| Avg. Volume (20D) | 600,500 |
| Open | 3.38 |
| Previous Close | 3.37 |
| Day's Range | 3.23 - 3.44 |
| 52-Week Range | 1.30 - 10.00 |
| Beta | 0.91 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...
Analyst Forecast
According to 4 analyst ratings, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 337.32% from the latest price.
Stock Forecasts
14 hours ago · seekingalpha.com
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsCorvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointe...
